Examination of 9a’s efficacy in a panel of pancreatic cancer cell lines with varied mutational status and reliance on KRAS suggests compound binding to other G4 structures, as there was no identified correlation with KRAS dependency and compound 9a’s activity. The gene discussed is KRAS; the disease is pancreatic neoplasm.